Drugs / RP-1664
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06232408 | Feb 2024 → Aug 2025 | cancer or benign tumor | Repare Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP-1664 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06232408 ↗ |
| Action | Inhibit | “resulting in the identification of RP-1664, a potent inhibitor of PLK4 with an excellent pharmacokinetic profile in preclinical species.” PMID 40378279 ↗ May 2025 |
| Target | PLK4 | “resulting in the identification of RP-1664, a potent inhibitor of PLK4 with an excellent pharmacokinetic profile in preclinical species.” PMID 40378279 ↗ May 2025 |